250 related articles for article (PubMed ID: 34506552)
1. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies.
Ali T; Sisay M; Tariku M; Mekuria AN; Desalew A
PLoS One; 2021; 16(9):e0257129. PubMed ID: 34506552
[TBL] [Abstract][Full Text] [Related]
2. Zuclopenthixol dihydrochloride for schizophrenia.
Bryan EJ; Purcell MA; Kumar A
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005474. PubMed ID: 29144549
[TBL] [Abstract][Full Text] [Related]
3. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M; Hsieh CH; Kane JM; Correll CU
J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of self-medication in Ethiopia: a systematic review and meta-analysis of observational studies.
Sisay M; Mengistu G; Edessa D
BMC Pharmacol Toxicol; 2018 Sep; 19(1):56. PubMed ID: 30201045
[TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
Barnes TR; McPhillips MA
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
[TBL] [Abstract][Full Text] [Related]
6. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.
Bergman H; Walker DM; Nikolakopoulou A; Soares-Weiser K; Adams CE
Health Technol Assess; 2017 Aug; 21(43):1-218. PubMed ID: 28812541
[TBL] [Abstract][Full Text] [Related]
8. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
[TBL] [Abstract][Full Text] [Related]
10. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia.
Dilks S; Xavier RM; Kelly C; Johnson J
Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784
[TBL] [Abstract][Full Text] [Related]
11. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff SN; Hurford I; Lybrand J; Campbell EC
Neurol Clin; 2011 Feb; 29(1):127-48, viii. PubMed ID: 21172575
[TBL] [Abstract][Full Text] [Related]
12. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.
Widschwendter CG; Hofer A
Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484
[TBL] [Abstract][Full Text] [Related]
14. Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis.
Sisay M; Weldegebreal F; Tesfa T; Ataro Z; Marami D; Mitiku H; Motbaynor B; Teklemariam Z
BMC Pharmacol Toxicol; 2018 Dec; 19(1):86. PubMed ID: 30541613
[TBL] [Abstract][Full Text] [Related]
15. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
[No Abstract] [Full Text] [Related]
17. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
Patterson-Lomba O; Ayyagari R; Carroll B
BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
19. Intermittent drug techniques for schizophrenia.
Sampson S; Mansour M; Maayan N; Soares-Weiser K; Adams CE
Cochrane Database Syst Rev; 2013 Jul; (7):CD006196. PubMed ID: 23881657
[TBL] [Abstract][Full Text] [Related]
20. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.
Koning JP; Vehof J; Burger H; Wilffert B; Al Hadithy A; Alizadeh B; van Harten PN; Snieder H;
Psychopharmacology (Berl); 2012 Feb; 219(3):727-36. PubMed ID: 21750899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
